mRESVIA® (Respiratory Syncytial Virus Vaccine) - Moderna
Online: Moderna's Adverse Event Intake Portal or U.S. HHS's Vaccine Adverse Event Reporting System. Connect with us. Email: [email protected] Call: 1-866-MODERNA (1-866-663-3762) Monday - Friday 8:00 AM to 8:00 PM ET (closed holidays)
MRESVIA | FDA - U.S. Food and Drug Administration
Dec 26, 2024 · Active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older. Product Information
Efficacy and Safety of an mRNA-Based RSV PreF Vaccine in Older …
Dec 13, 2023 · Respiratory syncytial virus (RSV) can cause substantial morbidity and mortality among older adults. An mRNA-based RSV vaccine, mRNA-1345, encoding the stabilized RSV prefusion F glycoprotein,...
Moderna Receives U.S. FDA Approval for RSV Vaccine mRESVIA(R)
May 31, 2024 · Moderna expects to have mRESVIA available for eligible populations in the U.S. by the 2024/2025 respiratory virus season. Moderna has filed for mRNA-1345 approval with regulators in multiple markets around the world. About …
FDA approves Moderna’s mRNA RSV vaccine for older adults
May 31, 2024 · The US Food and Drug Administration has approved another vaccine that can help protect older people from respiratory syncytial virus, known as RSV. The shot, made by Moderna and sold under the ...
Moderna RSV Vaccine Summary | Vaccines & Immunizations
Jul 5, 2024 · mRESVIA is indicated for active immunization for the prevention of LRTD caused by RSV in individuals 60 years of age and older. When ordering vaccines directly from Moderna, there is a minimum order of 10 doses. Pre-ordering or …
Respiratory Syncytial Virus (RSV) Vaccine Safety - CDC
Jan 31, 2025 · Moderna RSV vaccine is approved for people ages 60 years and older to prevent LRTD caused by RSV. CDC recommends that all people ages 75 years and older and people ages 60 to 74 years who are at increased risk for severe RSV disease receive a single dose of RSV vaccine . 1
Introducing the World’s First mRNA Vaccine Against RSV - Moderna
May 31, 2024 · mRESVIA is Moderna’s mRNA vaccine approved in the U.S. to protect adults aged 60 years and over from severe lower respiratory tract disease (LRTD) caused by respiratory syncytial virus, or RSV, infection.
Respiratory syncytial virus (RSV) can cause substantial morbidity and mortality among older adults. An mRNA-based RSV vaccine, mRNA-1345, encoding the stabilized RSV prefusion F glycoprotein,...
ACIP Evidence to Recommendations for Use of Moderna RSV …
Sep 5, 2024 · Learn more about the ACIP Evidence to Recommendations for Use of Moderna RSV Vaccine (mResvia) in All Adults Aged ≥75 years and in Adults Aged 60–74 at Increased Risk of Severe RSV Disease.